Nasdaq

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

KT-621 (STAT6) and KT-294 (TYK2) have the potential to provide biologics-like activity with oral small molecule profiles KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and KT-294 ...
Medical Xpress

Scientists discover a rare missense variant in STAT6 that protects against asthma

Scientists at deCODE genetics and collaborators have published a study in the Journal of Allergy and Clinical Immunology reporting a rare missense variant in STAT6 that protects against asthma. Asthma ...
Nasdaq

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader

WATERTOWN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using ...
EurekAlert!

Data from Codiak’s exoASO™-STAT6 preclinical development program for the treatment of primary and metastatic hepatic cancers published in Science Advances

CAMBRIDGE, Mass., February 18, 2022 — Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of ...
Seeking Alpha

Nurix Therapeutics, Inc. (NRIX) Discusses Clinical and Preclinical Updates on BTK, STAT6, and IRAK4 Degrader Programs Transcript

Good morning, and welcome to the Nurix Therapeutics Conference Call. I'm Arthur Sands, President and CEO. And I'm joined today on this call by Gwenn Hansen, our Chief Scientific Officer; Paula ...
News Medical

Codiak's publication highlights the ability of exoASO-STAT6 to selectively target tumor-associated macrophages

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the online publication of a ...
BioWorld

STAT6 degradation of IL-4/13: preclinical data in atopic dermatitis

In allergic diseases, STAT6 is a critical transcription factor in the IL-4 and IL-13 signaling pathways and the key driver of Th2 inflammation. Because STAT6 functions through protein-protein and ...